Skip to content
ESPT
MARKETS / NASDAQ / Health care / Medical devices and instruments / ARAY
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Accuray Inc. ARAY

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$401.9M
▼ 12.3% YoY
$-49.2M
$-12.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Accuray Incorporated develops, manufactures, sells and supports radiation treatment delivery, planning, and data management solutions. Its CyberKnife and TomoTherapy platforms, including the Radixact System, deliver treatments such as stereotactic radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company also provides post-contract customer support, installation services, training, and other professional services. Its principal offices in the United States are located in Madison, Wisconsin and Santa Clara, California. The company manufactures its CyberKnife and TomoTherapy platforms in Madison, Wisconsin, and manufactures the linear accelerator for those platforms at its facility in Chengdu, China. As of June 30, 2025, the company had 990 employees, including 432 employed outside of the United States. Accuray Incorporated was incorporated in California in 1990, commenced operations in 1992, and reincorporated in Delaware in 2007.

Written from the business description in ACCURAY INC's annual report to the U.S. Securities and Exchange Commission, filed 28 August 2025. Every sentence was checked against that document before publication.

Growth

USD 401.9M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 401.9 · Net income -49.2
200M400M-50M-100M
2009201220152018202120242025
Compound annual growth
−3.5%
+0.3%
+0.1%
+4.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−12 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.6% · Net -12.2%
2%4%-10%-20%-30%
200920172025
ROE
FY2025 · ROE -80.1%
-50%
200920172025
Three returns, three denominators.
Gross margin27.7%
Operating margin-6.6%
Net margin-12.2%
EBITDAUSD -18.5M

Each USD of equity lost 80 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -12.8
15M30M-30M-60M
200920172025
Net buybacks $M Dividends $M
FY2022 · Dividends · · Net buybacks -2.2
5M10M-2M-3M
2019202020212022
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 443.7M
EquityUSD 41.7M
CashUSD 40.6M
Gross debtUSD 147.9M
Net debtUSD 107.2M
Current ratio1.50×

Net debt stands at 257% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ARAY, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.40.50.40.40.40.40.40.40.40.40.40.40.40.30.40.20.2
Operating income $B−0.00.00.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.00.0
EBITDA $B−0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.1−0.0−0.00.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.00.0
Free cash flow $B−0.0−0.0−0.00.0−0.00.0−0.0−0.00.0−0.00.0−0.0−0.0−0.1−0.00.0−0.0
EPS, diluted $◌−0.02−0.16−0.10−0.06−0.070.04−0.19−0.28−0.36−0.32−0.51−0.47−1.41−1.02−0.440.05
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−80.1−2.5−31.5−17.4−8.8−9.56.7−33.4−50.2−55.7−37.7−46.1−34.5−75.0−35.3−13.21.7
Shares out B0.120.110.100.100.090.090.090.090.090.080.080.080.080.070.070.07◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image